Duration of Response (Unstratified, ITT Responders)
Pertuzumab +
Trastuzumab + AI (n =
69)
Trastuzumab + AI
(n = 59)
Median,
months
27.10
15.11
(95% CI)
(14.13, –)
(12.09, 20.96)
∆,
months
11.99
HR (95%
CI)
0.57 (0.36, 0.91)
p-value
0.0181
69 69 69 63 63 54 54 52 50 45 43 41 41 38 38 37 36 36 35 35 32 29 29 28 27 26 23 23 20 17 14 12 11 9 9 6 4 4 3 3 1 0
59 59 59 57 55 47 47 44 43 35 35 35 34 29 28 26 25 22 22 19 18 17 16 15 15 11 8 8 7 6 6 4 4 3 2 2 1 1 0 0 0 0
N at risk
Months
Event-free Probability (%)
100
90
80
70
60
50
40
30
20
10
0
40
38
37
36
35
34
33
32
31
30
29
28
27
26
25
24
23
22
21
20
19
18
17
16
15
14
13
12
11
10
9 8 7 6 5 4 3 2 1 0
41
39
Median
Pertuzumab + Trastuzumab + AI
Trastuzumab + AI
Unstratified analysis based upon Kaplan
–
Meier approach. HR from a stratified Cox proportional hazards model including stratification factors from IXRS.
